Showing 8381-8390 of 10142 results for "".
- American Academy of Dermatology Elects New Officers, Board Membershttps://practicaldermatology.com/news/american-academy-of-dermatology-elects-new-officers-board-members/2457825/The American Academy of Dermatology named its new officers and board members who will represent the more than 19,000 physicians who specialize in the diagnosis and medical, surgical and cosmetic treatment of skin, hair, and nail conditions. These officers and board members, all of whom are board-
- FDA Approves Label Update for Cimzia Addressing Low Risk of Fetal Exposurehttps://practicaldermatology.com/news/fda-approves-label-update-for-cimzia-addressing-low-risk-of-fetal-exposure/2457828/The FDA has approved a label update that includes pharmacokinetic data showing negligible to low transfer of Cimzia® (certolizumab pegol) through placenta and minimal transfer to breast milk fr
- New Recommendations Aim to Minimize Biotin Interference in Clinical Immunoassayshttps://practicaldermatology.com/news/new-recommendations-aim-to-minimize-biotin-interference-in-clinical-immunoassays/2457842/As the popularity of biotin has grown, so has the incidence of this vitamin interfering with critical medical tests, and now a review in The Journal of Applied Laboratory Medicine provides expert recommendat
- Novartis' Xolair Recommended in New Global Chronic Urticaria Guidelinehttps://practicaldermatology.com/news/novartis-xolair-recommended-in-new-global-chronic-urticaria-guideline/2457849/A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines. Xolair is the only licensed treatment option for CSU, a type of CU, for pat
- Vit D Levels Elevated in Acnehttps://practicaldermatology.com/news/vit-d-levels-higher-in-acne/2457867/Levels of vitamin D are higher in acne patients, compared to age/sex matched controls. Researchers found a significant inverse relation between level of 25 hydroxy vitamin D and severity of acne vulgaris before treatment, according to a study in Journal of Cosmetic Dermatology.
- MainPointe Pharmaceuticals to Purchase and License Mission's Consumer Productshttps://practicaldermatology.com/news/mainpointe-pharmaceuticals-to-purchase-and-license-missions-consumer-products/2457868/Mission Pharmacal Company has recently divested several consumer products to MainPointe Pharmaceuticals, LLC. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewa
- ISDIN AGE Contour Launches for Face and Neckhttps://practicaldermatology.com/news/isdin-age-contour-launches-for-face-and-neck/2457869/ISDIN has launched ISDIN AGE Contour, a triple action face and neck cream packed with ingredients to fight three key aspects of skin aging. Formulated with a tripeptide complex con
- New DermTech Research Validates Gene Expression Against High-Risk DNA Mutations Providing Objective Information for the Diagnosis of Melanomahttps://practicaldermatology.com/news/new-dermtech-research-validates-gene-expression-against-high-risk-dna-mutations-providing-objective-information-for-the-diagnosis-of-melanoma/2457871/DermTech, Inc. presented a late breaking abstract—“Validation of Noninvasive Gene Expression (PLA) Against High Risk Driver Mutations (BRAF, NRAS, and TERT) in Cutaneous Melanoma” —at the 76th Annual Meeting of the American Academy of Dermatology (AAD) in San Di
- Meet the Newest AAD Officers and Board Membershttps://practicaldermatology.com/news/meet-the-newest-aad-officers-and-board-members/2457876/Suzanne M. Olbricht, MD, FAAD, a Boston-based dermatologist, will take the helm of the American Academy of Dermatology (AAD) as the new President. Her one-year term officially begins on Tuesday, Feb. 20, at the conclusion of the 2018 AAD Annual Meeting in San Diego. Dr. Olbricht is an ass
- Biofrontera Rings Nasdaq Market Closing Bellhttps://practicaldermatology.com/news/biofrontera-rings-nasdaq-closing-bell/2457881/Biofrontera AG the specialist for the treatment of sun-induced skin cancer, visited the Nasdaq MarketSite in Times Square. In honor of the occasion, Prof. Hermann Lübbert, PhD, Chief Executive Officer of Biofrontera rang the Closing Bell